Enhanced Group’s $2.95 shares offer asymmetric upside if media-driven telehealth subscriptions scale, but dilution, regulation and cash execution make ENHA highly speculative.
Enhanced Group Inc. (NYSE: ENHA) operates as a pioneer at the intersection of elite sports entertainment, digital healthcare, and performance medicine [cite: 1]. Headquartered in Greenwich, Connecticut, the company transitioned to the public markets on May 7, 2026, through a business combination with A Paradise Acquisition Corp., a special purpose acquisition company (SPAC), at an initial transaction value of $1.2 billion [cite: 1, 2]. The primary operational model integrates two mutually reinforcing business segments: a high-visibility global sports property and a direct-to-consumer digital health platform [cite: 1, 3]. The first segment, the Enhanced Games, is a live, multi-sport competition platform designed to showcase both enhanced and non-enhanced athletes striving for world-record performances under medically supervised conditions [cite: 4]. The second segment, Live Enhanced, is a direct-to-consumer digital telehealth platform providing physician-guided physical performance protocols, over-the-counter supplement blends, longevity therapies, and clinician-guided prescription-based hormone replacement treatments [cite: 1, 5].
The consolidated revenue model spans multiple channels [cite: 1]. The Sports segment generates revenue through live event sponsorships, global brand partnerships, media licensing, and digital broadcasting rights [cite: 1, 6]. The Consumer Telehealth segment generates recurring, subscription-based sales of tailored performance and longevity products directly through the Live Enhanced platform [cite: 1, 6]. Geographically, corporate headquarters and digital health delivery are centered in the United States, while elite athlete clinical trials and physical training regimens are conducted in Abu Dhabi, United Arab Emirates, under the clinical oversight of the Abu Dhabi Department of Health [cite: 1, 3, 7]. The primary customer base consists of health-conscious individuals, performance-focused athletes, and aging consumers seeking preventative care, peptide therapies, or hormonal optimization [cite: 8, 9].
Consumers select Live Enhanced over traditional telehealth options due to its focus on physical optimization rather than restoration [cite: 10]. Traditional competitors typically address pathological or cosmetic issues to return patients to an average baseline [cite: 10]. In contrast, Enhanced Group focuses on maximizing physical and cognitive potential beyond traditional baselines, leveraging clinical insights derived directly from elite athletes to validate its direct-to-consumer product offerings [cite: 10, 11].
The economic engine of Enhanced Group relies on a marketing model conceptually akin to the Red Bull playbook [cite: 12]. Red Bull utilizes high-profile extreme sports properties to generate organic media reach, converting sports viewership into high-margin consumer product demand [cite: 12]. Similarly, Enhanced Group leverages the global attention surrounding the Enhanced Games as a low-cost, high-conversion customer acquisition funnel for its Live Enhanced telehealth platform [cite: 12, 13]. The live broadcast of athletes breaking world records on screen validates the clinical performance stacks sold on the telehealth platform, aiming to lower organic customer acquisition costs (CAC) through direct athlete affiliate channels and content-to-commerce integrations [cite: 13].
The primary commercial product is the "Thor Protocol" stack, a comprehensive, clinician-supervised performance regimen co-created with champion strength athlete Hafthor "Thor" Björnsson [cite: 14]. This specialized protocol integrates three primary therapies designed to address age-related decline across multiple physiological pathways: Testosterone Cypionate injections to maintain lean body composition, energy, and physical vitality; Intravenous or Subcutaneous NAD+ therapies to restore cellular energy metabolism and mitochondrial efficiency; and daily low-dose Tadalafil to promote nitric oxide-mediated vasodilation to optimize circulation, vascular flow, and endothelial function [cite: 14, 15, 16].
The company's competitive moat is driven by its proprietary clinical dataset [cite: 11]. Enhanced Group sponsors institutional review board (IRB)-approved clinical trials evaluating elite athletes undergoing medically supervised performance protocols [cite: 11, 17]. This rigorous documentation of clinical dosages, physiological responses, and athletic outcomes establishes a baseline for translating elite-level protocols directly into personalized consumer stacks [cite: 11]. Additionally, onboarding medical biomarker histories, lab tests, and doctor diagnoses onto the Live Enhanced platform creates switching costs, locking consumers into the ecosystem due to the friction of migrating personal medical history to alternative providers [cite: 6, 13, 15].
The addressable market opportunity spans global peptide therapeutics and digital telehealth [cite: 1, 17]. Favorable regulatory tailwinds, such as the potential FDA reclassification of 14 key Category 2 peptides to Category 1, are expected to open high-margin compounding options for direct-to-consumer wellness platforms [cite: 17].
| Market Segment | Current Estimated Value | Projected Future Value | Timeline | Source |
|---|---|---|---|---|
| Global Peptide Therapeutics | \$52 Billion | \$87 Billion | By 2035 | [cite: 17] |
| Broad Peptide Market (incl. non-GLP-1) | \$80 - \$140 Billion | Multi-year Expansion | Secular Bull | [cite: 9] |
| Weight Loss / GLP-1 Class | \$65 Billion | Continued Growth | Secular Bull | [cite: 9] |
The competitive landscape consists of traditional digital health companies and incumbent sports organizations [cite: 2, 9]. Direct-to-consumer health peers, such as Hims & Hers Health Inc., utilize large digital marketing budgets but lack a high-impact, organic sports asset to capture consumer attention [cite: 9]. Conversely, incumbent sports institutions enforce strict anti-doping policies, leaving the enhanced physical optimization market unserved [cite: 2]. Through its dual-engine model, Enhanced Group positions itself as a distinct provider in performance medicine, gaining early momentum by securing over $32 million in contractual sponsorships for its inaugural live event, which exceeded its initial sports revenue guidance of $31 million [cite: 18].
The latest reported financial statements reflect the historical results of Enhanced Ltd. for the first fiscal quarter ended March 31, 2026, which were announced on May 4, 2026 [cite: 19, 20, 21]. Because this period preceded the closing of the de-SPAC business combination on May 7, 2026, and the subsequent launch of the Live Enhanced telehealth platform, the financial results depict a pre-revenue, high-burn phase of operations [cite: 2, 6, 20].
Due to the pre-revenue profile and elevated operating expenses, management included a going concern warning in its quarterly disclosures, noting that existing cash balances were insufficient to cover operational needs for the next twelve months without additional capital injections [cite: 20].
Following the end of the first quarter, Enhanced Group structured a $50 million strategic equity financing via a private investment in public equity (PIPE) transaction [cite: 25, 26]. This transaction, closed in three tranches, was led by Apeiron Investment Group (the family office of Chairman Christian Angermayer) alongside CEO Maximilian Martin and global institutional investors [cite: 25]. The securities were priced at $3.89 per share (representing the NYSE closing price on June 12, 2026) and included five-year warrants exercisable at $3.89 per share with anti-dilution adjustments [cite: 26, 27].
The PIPE strategic financing is structured as follows [cite: 28]:
* Tranche 1 (\$25.0 Million): Closed on June 17, 2026, generating immediate proceeds [cite: 27, 28]. A portion of these proceeds (\$11.75 million plus accrued interest) was used to fully repay and retire the working capital promissory note owed to Apeiron [cite: 27, 28, 29].
* Tranche 2 (\$11.75 Million): Closed on July 22, 2026, through the issuance of 3,020,565 Class A shares and accompanying warrants to Apeiron [cite: 28, 30].
* Tranche 3 (\$13.25 Million): Pending closing, tied to stockholder consent effectiveness around August 2026 [cite: 28].
Management anticipates that this $50 million capitalization, coupled with organic telehealth subscription revenue, will fund the company's operating plan through operational profitability targeted for fiscal year 2027 [cite: 8, 25].
The inaugural Enhanced Games held on May 24, 2026, in Las Vegas secured over $32 million in aggregate contractual sponsorship deal value across its commercial partner ecosystem [cite: 18]. Key partnerships were established with brands including ZOOP (a $10 million founding partner deal), Rumble (NASDAQ: RUM), Rezolve AI (NASDAQ: RZLV), Roku (NASDAQ: ROKU), Caliwater, Betr, and Frame Fitness [cite: 18, 31]. Because these contracts were secured ahead of the event, the company exceeded its full-year 2026 sports segment revenue guidance of $31 million [cite: 18].
Evaluating the valuation of Enhanced Group requires reconciling its pre-revenue historical financials with its newly scaled run-rate asset base.
* Price-to-Book (P/B) Ratio: 10.9x [cite: 32]. Given the nominal historical revenues, Price-to-Book represents the primary relative valuation metric used by analysts to assess capital efficiency [cite: 33].
* Enterprise Value (EV) / Revenue: Multiple calculations are currently distorted by the transition from a shell company to an operating entity [cite: 19]. Based on post-merger adjustments, the pro-forma enterprise value is approximately $383.23 million, with cash balances improving to $19.6 million as of June 30, 2026, following the closing of the first PIPE tranche [cite: 5, 28].
* Historical Multiples: Price-to-Earnings and Price-to-Sales are not representative of current run-rate operations due to the trailing net loss of $39.78 million [cite: 34].
The primary valuation drivers for the equity going forward include:
1. The customer retention rate and lifetime-value-to-CAC ratio on the Live Enhanced platform [cite: 6].
2. The long-term conversion rate of the one billion global media impressions into recurring telehealth subscribers [cite: 25, 35].
3. The successful closing of the third PIPE tranche of $13.25 million, which is crucial to maintaining a healthy capital position [cite: 28].
The primary operational risk is the company's historical capital consumption relative to its liquid resources [cite: 20, 28]. Despite the structured $50 million strategic financing, the cash balance as of June 30, 2026, was $19.6 million [cite: 28]. A significant delay or failure in executing the third PIPE tranche of $13.25 million would pressure the company's operational runway [cite: 28, 36]. Additionally, the company operates an unproven, dual-engine business model that demands synchronized execution between complex sports event production and a highly regulated medical telehealth platform [cite: 1, 6, 19].
Enhanced Group's telehealth and clinical trial programs are exposed to strict healthcare regulations [cite: 6, 37]. The medical compounds administered in the elite athlete studies—including testosterone esters, human growth hormone, and various stimulants—require precise clinical oversight and secure supply chains [cite: 11, 37]. Any change in telehealth prescribing laws, state-level licensing for digital health providers, or a regulatory crackdown on compounding pharmacies (specifically 503A facilities) would disrupt the company's product pipeline [cite: 6, 17]. Furthermore, because the company relies on the reclassification of Category 2 peptides to Category 1 to expand its high-margin offering, any adverse ruling by the FDA would limit its addressable market expansion [cite: 17].
Following the de-SPAC transaction, the company adopted a dual-class voting structure [cite: 38]. Class A shares carry one vote per share, while Class B shares carry ten votes per share but hold no economic rights to dividends, distributions, or liquidation [cite: 38]. As of July 17, 2026, there were 122,545,453 Class A shares and 258,837,933 Class B shares outstanding [cite: 29]. Enhanced Holdings LP (controlled by Chairman Christian Angermayer through Apeiron Investment Group) holds approximately 96.6% of the aggregate voting power [cite: 29, 30]. This concentration of voting power creates potential conflicts of interest, isolates minority shareholders from corporate governance influence, and renders the Class A stock ineligible for inclusion in major index benchmarks, which limits institutional liquidity [cite: 2, 38].
From a macroeconomic perspective, high interest rates increase the cost of capital for unprofitable growth firms, making future equity dilutions more expensive if the path to 2027 operational profitability is delayed [cite: 8, 25]. Additionally, a portion of the clinical trial logistics and athlete preparation occurs in Abu Dhabi [cite: 3]. Ongoing geopolitical instability and hostilities in the Middle East present risk factors that could disrupt these offshore clinical operations and delay the accumulation of proprietary performance datasets [cite: 3, 6].
This five-year forecasting model evaluates the equity trajectory of Enhanced Group from the base-level share price of $2.95 [cite: 39]. The valuation metrics assume a post-PIPE share count of 135,400,000 Class A shares and account for compounding dilution from warrant exercises and option pools over a five-year horizon [cite: 39].
The Base Case assumes a disciplined scale-up of the Live Enhanced telehealth platform and stable annual execution of the Enhanced Games [cite: 1, 6].
* Revenue Growth: Sports segment sponsorships and broadcast licensing stabilize, while the telehealth platform scales its subscription base, generating a consolidated five-year revenue compound annual growth rate ($CAGR$) of 45% starting from $45.0 million in Year 1 (2026) to $198.92 million in Year 5 (2031) [cite: 39].
* Margin Profile: Operates at a steady-state net income margin of 15% by Year 5, yielding net income of $29.84 million as marketing spend normalizes and organic conversion channels mature [cite: 13, 39].
* Share Count Dilution: A 3% annual dilution rate is applied due to the exercise of outstanding options and SAFE warrants, bringing the Class A outstanding count to 152.39 million shares in Year 5 [cite: 39, 40].
* Valuation Multiple: A conservative price-to-earnings (P/E) multiple of 22.0x is applied, aligning with mature digital health platforms [cite: 39].
* Calculations:
$\text{Year 5 EPS} = \frac{\$29.84 \text{ Million}}{152.39 \text{ Million Shares}} \approx \$0.196$ $\text{Implied Year 5 Share Price} = \$0.196 \times 22.0 \approx \$4.31$ $\text{5-Year Total Return} = \frac{\$4.31}{\$2.95} - 1 \approx 46.02\% \quad (\text{Annualized Return} \approx 7.87\%)$
The High Case assumes rapid consumer adoption of performance medicine, favorable FDA reclassifications of compound peptides, and global distribution of media rights [cite: 17, 35].
* Revenue Growth: Telehealth subscriptions experience accelerated demand driven by athlete-led marketing, while the Enhanced Games secure multi-year premium broadcast deals, generating a five-year revenue $CAGR$ of 60% starting from $55.0 million in Year 1 (2026) to $360.45 million in Year 5 (2031) [cite: 18, 39].
* Margin Profile: Achieves a highly efficient net income margin of 20%, resulting in Year 5 net income of $72.09 million [cite: 39].
* Share Count Dilution: Dilution rises to 5% annually to support expansion capital and equity incentives, reaching 164.58 million outstanding shares in Year 5 [cite: 39].
* Valuation Multiple: Employs an elevated P/E multiple of 28.0x, reflecting high-growth premium wellness positioning [cite: 39].
* Calculations:
$\text{Year 5 EPS} = \frac{\$72.09 \text{ Million}}{164.58 \text{ Million Shares}} \approx \$0.438$ $\text{Implied Year 5 Share Price} = \$0.438 \times 28.0 \approx \$12.26$ $\text{5-Year Total Return} = \frac{\$12.26}{\$2.95} - 1 \approx 315.75\% \quad (\text{Annualized Return} \approx 32.97\%)$
The Low Case reflects severe operational disruptions, regulatory restrictions on telehealth therapies, and high customer churn [cite: 6, 37].
* Revenue Growth: Regulatory actions limit compound peptide availability, and high churn rates impact subscriber growth, leading to a modest five-year revenue $CAGR$ of 15% starting from $35.0 million in Year 1 (2026) to $61.22 million in Year 5 (2031) [cite: 6, 39].
* Margin Profile: Elevated regulatory compliance costs and legal expenses compress net margins to 2%, yielding a nominal Year 5 net income of $1.22 million [cite: 6, 39].
* Share Count Dilution: Kept at a minimal 2% annual increase, resulting in 146.56 million shares outstanding in Year 5 [cite: 39].
* Valuation Multiple: A depressed exit multiple of 12.0x reflects low-growth, specialized healthcare businesses [cite: 39].
* Calculations:
$\text{Year 5 EPS} = \frac{\$1.22 \text{ Million}}{146.56 \text{ Million Shares}} \approx \$0.008$ $\text{Implied Year 5 Share Price} = \$0.008 \times 12.0 \approx \$0.10$ $\text{5-Year Total Return} = \frac{\$0.10}{\$2.95} - 1 \approx -96.60\% \quad (\text{Annualized Return} \approx -49.16\%)$
The following structured table defines the estimated share price trajectory across the 5-year forecast window, assuming a non-linear operational ramp-up:
| Scenario | Year 0 Price | Year 1 Price | Year 2 Price | Year 3 Price | Year 4 Price | Year 5 Price |
|---|---|---|---|---|---|---|
| High Case (USD) | \$2.95 | \$3.92 | \$5.22 | \$6.94 | \$9.23 | \$12.26 |
| Base Case (USD) | \$2.95 | \$3.17 | \$3.42 | \$3.69 | \$3.98 | \$4.31 |
| Low Case (USD) | \$2.95 | \$1.50 | \$0.76 | \$0.39 | \$0.20 | \$0.10 |
| Scenario | Revenue in Year 5 (USD M) | Margin / Earnings Assumption (%) | Valuation Multiple Assumption | Current Share Price (USD) | Implied Future Share Price (USD) | 5-Year Total Return (%) | Annualized Return (%) | Probability Weight (%) |
|---|---|---|---|---|---|---|---|---|
| High Case | \$360.45 | 20.0% / \$72.09M | 28.0x P/E | \$2.95 | \$12.26 | 315.75% | 32.97% | 25.0% |
| Base Case | \$198.92 | 15.0% / \$29.84M | 22.0x P/E | \$2.95 | \$4.31 | 46.02% | 7.87% | 55.0% |
| Low Case | \$61.22 | 2.0% / \$1.22M | 12.0x P/E | \$2.95 | \$0.10 | -96.60% | -49.16% | 20.0% |
Through a mathematical probability weighting, the estimated fair-value target price is calculated as:
$\text{Weighted Target Share Price} = (0.25 \times \$12.26) + (0.55 \times \$4.31) + (0.20 \times \$0.10) \approx \$5.46$
The probability-weighted target share price of $5.46 indicates that the stock is currently undervalued relative to its long-term operational potential [cite: 39].
ASYMMETRIC SPECULATIVE PATHWAY
This qualitative evaluation rates Enhanced Group across ten operational categories on a scale of 1–10.
Management Alignment: 8 / 10
Insiders maintain strong alignment with equity outcomes [cite: 41]. Co-founder and Chairman Christian Angermayer, through Apeiron Investment Group, led the $50 million PIPE strategic financing [cite: 25]. CEO Maximilian Martin personally committed $5.0 million to the private placement [cite: 26]. Together, insiders maintain a strong ownership position, which aligns executive incentives with long-term capital appreciation, though the concentration of voting power introduces structural corporate governance risks for Class A shareholders [cite: 2, 26].
Revenue Quality: 4 / 10
Historical revenues are nominal, and initial telehealth offerings are in the early stages of commercial expansion [cite: 6, 20]. This pre-revenue history is balanced by over $32 million in contractual event sponsorships, which points to a predictable, business-to-business pipeline [cite: 18]. Once subscription metrics stabilize on the Live Enhanced platform, the recurring monthly subscriber revenue is expected to improve overall revenue quality [cite: 6].
Market Position: 7 / 10
Enhanced Group has established a unique pioneer position within the performance medicine category [cite: 8, 15]. By directly challenging traditional anti-doping athletic frameworks, the brand has captured global media attention (nearly 4,000 mentions across platforms reaching 16.7 billion unique visitors) [cite: 35, 42]. The platform maintains a high share of voice in the enhanced athletic category, with no direct competitors operating a similar dual-engine model [cite: 1, 12].
Growth Outlook: 8 / 10
The secular growth drivers are robust, supported by a rising consumer focus on longevity, peptide utilization, and preventative healthcare [cite: 8]. Potential FDA regulatory reclassifications of Category 2 compounds would open a compounding pipeline for direct-to-consumer digital channels [cite: 17].
Financial Health: 3 / 10
Financial health is limited by the company's going concern status and elevated operating cash burn ($19.0 million cash outflow in Q1 2026) [cite: 20, 22]. While the $50 million strategic financing temporarily addresses near-term liquidity concerns, long-term balance sheet strength is dependent on achieving the 2027 operational profitability targets [cite: 8, 25].
Business Viability: 5 / 10
The viability of the business model is highly sensitive to regulatory changes [cite: 6, 37]. Telehealth compliance, prescription guidelines, and offshore clinical trial integrity represent operational choke points [cite: 3, 6, 37]. However, if the clinical trial database continues to build and the consumer platform retains its subscribers, the platform's viability will improve [cite: 6, 11].
Capital Allocation: 6 / 10
Management is prioritizing capital toward high-return digital acquisition channels and proprietary dataset collection [cite: 11, 35]. A portion of the PIPE proceeds was allocated to retire the outstanding $11.75 million working note owed to Apeiron, which cleared short-term debt but diluted equity holders [cite: 27, 28]. Future capital allocation must show discipline regarding athlete prize expenditures [cite: 37].
Analyst Sentiment: 7 / 10
Wall Street sentiment is positive but limited in coverage breadth [cite: 43]. Professional analysts at Lucid Capital Markets initiated coverage with a Buy rating and a $15.00 price target [cite: 23], while Canaccord Genuity initiated with a Buy rating and a $6.00 price target [cite: 23, 43]. This yields a consensus target of $10.50, suggesting the equity is undervalued at current levels [cite: 43, 44].
Profitability: 2 / 10
The company is currently unprofitable, recording a net loss of $16.43 million in the latest quarter and accumulating a deficit of $48.5 million [cite: 20, 22]. Standalone profitability for the Enhanced Games is targeted for 2027, and overall platform profitability depends on achieving scale [cite: 8, 25, 45].
Track Record: 3 / 10
As a newly transitioned de-SPAC with a short operating history, the company has a limited public track record of execution [cite: 2, 46]. The equity price has experienced extreme volatility, declining over 70% from its 52-week high of $14.00 [cite: 5, 7].
| Qualitative Dimension | Assigned Score (1–10) | Core Supporting Factor |
|---|---|---|
| Management Alignment | 8 / 10 | High insider PIPE participation offset by voting power concentration [cite: 25, 26, 29]. |
| Revenue Quality | 4 / 10 | Transitioning from pre-revenue to contractual event sponsorships [cite: 6, 18]. |
| Market Position | 7 / 10 | Unique positioning within optimized athletics; strong media reach [cite: 35, 42]. |
| Growth Outlook | 8 / 10 | Multi-billion-dollar peptide and hormone replacement tailwinds [cite: 17]. |
| Financial Health | 3 / 10 | Going concern designation and elevated pre-revenue operational cash burn [cite: 20, 28]. |
| Business Viability | 5 / 10 | Innovative dual-engine platform exposed to significant regulatory risk [cite: 1, 6, 37]. |
| Capital Allocation | 6 / 10 | Retiring of Apeiron debt balanced by direct platform investments [cite: 27, 28]. |
| Analyst Sentiment | 7 / 10 | Bullish Wall Street targets with limited initiating coverage [cite: 43, 44]. |
| Profitability | 2 / 10 | High current net losses with standalone event breakeven targeted for 2027 [cite: 8, 20]. |
| Track Record | 3 / 10 | Post-merger transition phase with limited public financial history [cite: 2, 22, 46]. |
| Blended Score | 5.3 / 10 | Weighted Average Profile representing a high-risk category pioneer. |
The qualitative scorecard, scoring distributions, and blended calculations presented above are provided strictly for educational and analytical purposes. This evaluation does not constitute financial advice, investment recommendations, or an endorsement to buy, sell, or hold securities of Enhanced Group Inc.
HIGH-RISK SPECULATIVE RATING
The investment thesis for Enhanced Group hinges on the successful monetization of global consumer attention [cite: 12]. Through its sports property, the company has built a high-visibility marketing platform capable of reaching over one billion viewers globally without traditional capital expenditures [cite: 12, 25]. The central question is whether the executive team can efficiently funnel this brand awareness into high-margin, recurring consumer subscriptions on the Live Enhanced telehealth platform [cite: 8, 13].
In summary, Enhanced Group represents a speculative, asymmetric opportunity [cite: 9]. The company is currently undervalued relative to its probability-weighted target share price of $5.46 and is backed by committed inside capital [cite: 25, 26]. However, investors must accept elevated regulatory exposure and capital execution risks [cite: 6, 20, 37].
This analysis is presented exclusively for informational and educational purposes. It does not provide individualized investment advice or patient-specific treatment plans. Investors are urged to consult with qualified financial professionals before making any capital decisions.
SPECULATIVE VOLATILITY PLAY
Enhanced Group's Class A common stock trades at approximately $2.95, establishing a technical support level near its 52-week low of $2.35, while remaining significantly below its 52-week high of $14.00 [cite: 5, 7]. The equity exhibits a bearish medium-term trend, trading 64.3% below its 200-day Simple Moving Average (SMA) of $8.46 and 15.4% below its 50-day SMA of $3.57 [cite: 5]. Short-term price action is influenced by the rising short interest (which increased 129.7% in June 2026 to 2.28 million shares, representing 1.86% of the public float) [cite: 48] and the technical overhang of the S-1 resale registration statements [cite: 28]. The short-term outlook is expected to consolidate as the market awaits technical stabilization post-PIPE tranche distributions and the next operational update in mid-August [cite: 28, 35].
OVERSOLD CONSOLIDATION PHASE
View Enhanced Group Inc. (ENHA) stock page
Loading the interactive version of this report…